Experienced in Virilizing Ovarian Tumor

Dr. Jared D. Acoba

Hematology Oncology | Hematology | Oncology
The Queens Medical Center
1301 Punchbowl St, 
Honolulu, HI 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Experienced in Virilizing Ovarian Tumor
The Queens Medical Center
1301 Punchbowl St, 
Honolulu, HI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jared Acoba is a Hematologist Oncology specialist and a Hematologist in Honolulu, Hawaii. Dr. Acoba is rated as an Experienced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Gastrostomy. Dr. Acoba is currently accepting new patients.

His clinical research consists of co-authoring 40 peer reviewed articles and participating in 22 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in HI
Hospital Affiliations
Molokai General Hospital
The Queens Medical Center
Kuakini Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AlohaCare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Hawaii Medical Assurance Association
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

THE QUEENS MEDICAL CENTER
1301 Punchbowl St, Honolulu, HI 96813

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)
Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)
Enrollment Status: Recruiting
Publish Date: May 22, 2025
Intervention Type: Procedure, Other
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study
NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Procedure
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Ramucirumab, Erlotinib, Gefitinib, Osimertinib
Study Phase: Phase 3
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Device, Biological, Other, Drug
Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab
Study Phase: Phase 2
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Procedure, Other, Biological, Drug
Study Drugs: Atezolizumab, Glycosylated Recombinant IL-7
Study Phase: Phase 2
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2024
Intervention Type: Drug, Other
Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate
Study Phase: Phase 2
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
Phase Ib/II Study of ALT-803 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Pancreatic Cancer
Phase Ib/II Study of ALT-803 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: January 27, 2020
Intervention Type: Biological
Study Phase: Phase 1
Phase I Study of Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
Phase I Study of Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
Enrollment Status: Withdrawn
Publish Date: November 08, 2019
Intervention Type: Radiation, Drug
Study Phase: Phase 1
View 20 Less Clinical Trials

40 Total Publications

Comprehensive Analysis of Factors Associated with Treatment Delays in Asian, Native Hawaiian, and Other Pacific Islander Patients with Colorectal Cancer.
Comprehensive Analysis of Factors Associated with Treatment Delays in Asian, Native Hawaiian, and Other Pacific Islander Patients with Colorectal Cancer.
Journal: Journal of gastrointestinal cancer
Published: July 06, 2025
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Paula S. Lee
Obstetrics and Gynecology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Paula S. Lee
Obstetrics and Gynecology | Oncology

Pali Momi Medical Center

98 -1005 Moanalua Rd, 
Aiea, HI 
 (7.7 miles away)
808-485-4500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Paula Lee is an Obstetrics and Gynecologist and an Oncologist in Aiea, Hawaii. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Hysterectomy, and Ureteral Reconstruction. Dr. Lee is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Michael E. Carney
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Michael E. Carney
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Kapiolani Medical Specialists

1319 Punahou St, 
Honolulu, HI 
 (1.5 miles away)
808-983-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Carney is a Gynecologic Oncologist and an Oncologist in Honolulu, Hawaii. Dr. Carney is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Oophorectomy, and Hysterectomy. Dr. Carney is currently accepting new patients.

Advanced in Virilizing Ovarian Tumor
Dr. Keith Y. Terada
Obstetrics and Gynecology | Oncology
Advanced in Virilizing Ovarian Tumor
Dr. Keith Y. Terada
Obstetrics and Gynecology | Oncology
1329 Lusitana St, #803, 
Honolulu, HI 
 (0.2 miles away)
808-526-2477
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Keith Terada is an Obstetrics and Gynecologist and an Oncologist in Honolulu, Hawaii. Dr. Terada is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Hysterectomy, and Colonoscopy. Dr. Terada is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Acoba's expertise for a condition
ConditionClose
    View All 28 Advanced Conditions
    View All 80 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile